Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Hematology · Myelodysplastic Syndrome with Ring Sideroblasts

Managing Your Anemia: The Standard of Care

At a Glance

The standard of care for managing anemia in MDS-RS focuses on a stepped approach starting with observation. When symptoms worsen, doctors prescribe medications like ESAs or luspatercept to boost red blood cell production. If these fail, regular blood transfusions become the main treatment.

Treating Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS) is primarily focused on one goal: managing anemia and improving your quality of life [1]. Because this is typically a slow-moving condition, treatment is often a “ladder” that you climb only when symptoms make it necessary [2].

The Treatment Pathway

Doctors generally follow a step-by-step approach based on how you feel and what your blood tests show:

  1. Watch and Wait (Observation): If your anemia is mild and you aren’t feeling significant fatigue or shortness of breath, your doctor may simply monitor your blood counts every few months. Many patients stay in this stage for years [2].
  2. Addressing the Anemia (First-Line): When symptoms begin to interfere with daily life, the focus shifts to boosting your red blood cell production.
  3. Transfusion Support: If medications aren’t enough to keep your energy up, regular blood transfusions become the mainstay of care [3].

Boosting Your Blood: Medications

There are newer and older medications used to help your body make more functional red blood cells. Note that neither ESAs nor luspatercept work overnight; they typically take 4 to 8 weeks of treatment before you see a noticeable improvement in your hemoglobin levels.

Erythropoiesis-Stimulating Agents (ESAs)

ESAs (like epoetin alfa or darbepoetin) act like a “gas pedal” for your bone marrow, telling it to produce more red blood cells [4]. These work best for patients whose natural levels of erythropoietin (a hormone made by the kidneys) are low [2].

  • Potential Side Effects: ESAs can occasionally cause hypertension (high blood pressure) and carry a risk of blood clots.

Luspatercept: Helping Cells “Grow Up”

Luspatercept is a newer, “first-in-class” medication known as an erythroid maturation agent [5].

  • How it works: In MDS-RS, your body makes plenty of “baby” red blood cells, but they get stuck and can’t mature into adult cells that carry oxygen [6]. Luspatercept helps them “grow up” and enter your bloodstream [7][8].
  • The Evidence: The COMMANDS trial showed that for many patients who have not yet tried other treatments, luspatercept was more effective than traditional ESAs at increasing hemoglobin and reducing the need for transfusions [9][10].
  • Potential Side Effects: Patients receiving luspatercept may experience fatigue, musculoskeletal pain (bone or joint pain), and hypertension [11].

Managing Transfusions and Iron Overload

If medications cannot keep your hemoglobin at a comfortable level, you may need Red Blood Cell (RBC) Transfusions. Doctors typically wait until your hemoglobin drops below 7 to 8 g/dL, or when you begin experiencing severe, unmanageable symptoms [3].

While transfusions provide an immediate energy boost, they come with a long-term side effect: iron overload [12]. Every bag of blood contains a significant amount of iron. Since the body has no natural way to get rid of extra iron, it can build up in your heart and liver over time [12].

  • Monitoring: Your doctor will monitor your ferritin levels (a marker of iron stores) [13].
  • Chelation Therapy: If iron levels get too high, you may need “chelation” medications (like deferasirox) that bind to the iron and help your body flush it out [12].

New Options on the Horizon

For patients who do not respond to ESAs or luspatercept, newer drugs like imetelstat have recently been approved to help manage anemia in lower-risk MDS [14][15]. However, imetelstat requires careful monitoring as it frequently causes significant cytopenias (drops in your other blood counts, specifically neutropenia and thrombocytopenia) [14].

Common questions in this guide

What is the first step in treating MDS-RS?
If your anemia is mild and you are not experiencing significant symptoms like fatigue or shortness of breath, doctors often recommend a watch and wait approach. This means they will regularly monitor your blood counts without starting active treatment.
How long does it take for ESAs or luspatercept to work?
Neither ESAs nor luspatercept provide immediate relief for anemia symptoms. It typically takes 4 to 8 weeks of consistent treatment before you will notice an improvement in your hemoglobin levels and energy.
How does luspatercept help treat MDS-RS?
In MDS-RS, your bone marrow produces immature red blood cells that fail to fully develop. Luspatercept is a medication that helps these cells mature so they can properly enter your bloodstream and carry oxygen throughout your body.
When will I need to start getting blood transfusions?
Doctors generally recommend starting blood transfusions when your hemoglobin drops below 7 to 8 g/dL, or when your anemia symptoms become severe and unmanageable with medications alone.
Why do I need my ferritin levels checked if I get blood transfusions?
Because every bag of transfused blood contains a large amount of iron, frequent transfusions can cause iron to build up in organs like your heart and liver. Your doctor will track your ferritin levels to monitor for iron overload, which can be treated with chelation therapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my serum erythropoietin (EPO) level, and does it make me a good candidate for ESAs?
  2. 2.Given the COMMANDS trial results, should I start with luspatercept instead of an ESA as my first treatment?
  3. 3.What potential side effects should I watch for when starting luspatercept or an ESA?
  4. 4.At what specific hemoglobin level do you recommend I receive a blood transfusion?
  5. 5.Is my ferritin level high enough that we should discuss iron chelation therapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

    Fenaux P, Platzbecker U, Mufti GJ, et al.

    The New England journal of medicine 2020; (382(2)):140-151 doi:10.1056/NEJMoa1908892.

    PMID: 31914241
  2. 2

    A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS.

    Fenaux P, Santini V, Spiriti MAA, et al.

    Leukemia 2018; (32(12)):2648-2658 doi:10.1038/s41375-018-0118-9.

    PMID: 29895954
  3. 3

    Exploring the rationale for red cell transfusion in myelodysplastic syndrome patients: emerging data and future insights.

    Finelli C, Parisi S, Paolini S

    Expert review of hematology 2022; (15(5)):411-421 doi:10.1080/17474086.2022.2077721.

    PMID: 35549626
  4. 4

    Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.

    Platzbecker U, Santini V, Komrokji RS, et al.

    Leukemia 2023; (37(11)):2314-2318 doi:10.1038/s41375-023-02031-7.

    PMID: 37752285
  5. 5

    Treatment patterns and outcomes with luspatercept in patients with lower-risk myelodysplastic syndromes: A retrospective US cohort analysis.

    Mukherjee S, Brown-Bickerstaff C, Falkenstein A, et al.

    HemaSphere 2024; (8(1)):e38 doi:10.1002/hem3.38.

    PMID: 38434524
  6. 6

    Development of luspatercept to treat ineffective erythropoiesis.

    Kubasch AS, Fenaux P, Platzbecker U

    Blood advances 2021; (5(5)):1565-1575 doi:10.1182/bloodadvances.2020002177.

    PMID: 33687432
  7. 7

    New drugs for myeloid neoplasms with ring sideroblasts: Luspatercept vs imetelstat.

    Tefferi A

    American journal of hematology 2021; (96(7)):761-763 doi:10.1002/ajh.26197.

    PMID: 33861878
  8. 8

    The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia.

    Delgado J, Voltz C, Stain M, et al.

    HemaSphere 2021; (5(8)):e616 doi:10.1097/HS9.0000000000000616.

    PMID: 34291195
  9. 9

    Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.

    Garcia-Manero G, Santini V, Zeidan AM, et al.

    Advances in therapy 2025; (42(7)):3576-3589 doi:10.1007/s12325-025-03208-5.

    PMID: 40377899
  10. 10

    Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.

    Platzbecker U, Della Porta MG, Santini V, et al.

    Lancet (London, England) 2023; (402(10399)):373-385 doi:10.1016/S0140-6736(23)00874-7.

    PMID: 37311468
  11. 11

    Treatment options for lower-risk myelodysplastic syndromes. Where are we now?

    Volpe VO, Komrokji RS

    Therapeutic advances in hematology 2021; (12()):2040620720986641 doi:10.1177/2040620720986641.

    PMID: 33505645
  12. 12

    Transfusion avoidance in myelodysplastic neoplasms.

    Griffiths EA

    Current opinion in hematology 2024; (31(2)):40-46 doi:10.1097/MOH.0000000000000794.

    PMID: 37982261
  13. 13

    Role of Zinc and Copper in Erythropoiesis in Patients on Hemodialysis.

    Takahashi A

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 2022; (32(6)):650-657 doi:10.1053/j.jrn.2022.02.007.

    PMID: 35248722
  14. 14

    Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.

    Santini V, Zeidan AM, Van Eygen K, et al.

    Leukemia 2026; (40(2)):397-409 doi:10.1038/s41375-025-02831-z.

    PMID: 41526614
  15. 15

    Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents.

    Hoff FW, Chung SS, Zeidan AM, Madanat YF

    JCO oncology practice 2025; OP2400910 doi:10.1200/OP-24-00910.

    PMID: 40763320

This page provides educational information about the standard of care for managing anemia in MDS-RS. It does not replace professional medical advice. Always discuss your symptoms, treatment timeline, and medication options with your hematologist or healthcare provider.

Get notified when new evidence is published on Acquired idiopathic sideroblastic anemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.